Summary:
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients with Rheumatoid Arthritis, 254516
Qualified Participants Must:
• Must be between age 18-64 years of age
•
Must be diagnosed with Rheumatoid Arthritis
Qualified Participants May Receive:
Qualified Participants receive all the trial related treatment for free plus more than $5000 for their participation.